Dengue Vaccine Research Report 2024 with Focus on 40+ Players Including Biological E, GSK, Instituto Butantan, Panacea Biotec, Sanofi, Takeda, Vabiotech - Market Forecast to 2030


Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "Dengue Vaccine - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The global market for Dengue Vaccine was estimated at US$589.0 Million in 2023 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of 15.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.



Clinical trials for the dengue vaccine have shown varied efficacy rates across different serotypes and age groups, with overall efficacy hovering around 60%. The vaccine's effectiveness is notably higher in individuals who have had a previous dengue infection, underscoring its utility in endemic regions where such exposure is common.

Public health benefits of the vaccine include reduced hospitalization rates and a decrease in severe dengue cases, which are significant in helping ease the burden on healthcare systems in affected regions. The vaccine is thus considered a critical tool in the fight against dengue, particularly in high-prevalence areas. By reducing the incidence of dengue, it not only saves lives but also reduces economic loss related to healthcare costs and lost productivity due to illness.

What Are the Challenges and Considerations in the Deployment of the Dengue Vaccine?

The deployment of the dengue vaccine has faced several challenges and ethical considerations. One major issue is determining vaccine eligibility, particularly in identifying individuals previously infected by the dengue virus. This requires reliable serological testing, which can be costly and logistically challenging in resource-poor settings.

There's also the risk of vaccine-related severe dengue in seronegative vaccine recipients, which has led to controversies and public distrust in some regions following early roll-outs. These challenges necessitate careful planning and public communication strategies to maximize benefits and minimize risks associated with vaccination. Additionally, ongoing research and surveillance are crucial to monitor long-term vaccine safety and effectiveness, especially as the virus evolves and different population dynamics come into play.

What Drives the Growth in the Dengue Vaccine Market?

The growth in the dengue vaccine market is driven by several factors, primarily the high burden of disease in over 100 countries, increasing the demand for effective preventive measures. The expansion of endemic areas due to global warming and increased urbanization, which create ideal breeding conditions for mosquitoes, also spur the need for vaccines. Furthermore, growing international travel continues to introduce dengue into new regions, raising global concern and demand for vaccination.

Advances in vaccine technology and increased funding for dengue research have accelerated the development and improvement of dengue vaccines, making them more accessible and affordable. Public-private partnerships and initiatives by global health bodies like the World Health Organization (WHO) to promote vaccination as part of integrated dengue prevention plans also contribute to the growth of the market. These factors, combined with a heightened awareness of the impact of dengue and the availability of preventive options, ensure a dynamic and expanding market for the dengue vaccine.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Government Institutions End-Use segment, which is expected to reach US$774.6 Million by 2030 with a CAGR of a 14.2%. The Hospitals End-Use segment is also set to grow at 16.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $151.9 Million in 2023, and China, forecasted to grow at an impressive 20.1% CAGR to reach $412.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players such as Biological E. Ltd., GlaxoSmithKline plc, Instituto Butantan, and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Attributes:

Report AttributeDetails
No. of Pages193
Forecast Period2023 - 2030
Estimated Market Value (USD) in 2023$589 Million
Forecasted Market Value (USD) by 2030$1600 Million
Compound Annual Growth Rate15.8%
Regions CoveredGlobal



Key Topics Covered:

MARKET OVERVIEW

  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Dengue Vaccine - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)

MARKET TRENDS & DRIVERS

  • Rising Global Prevalence of Dengue Fever Drives Urgency for Vaccine Development
  • Increasing Government and NGO Funding Propels Dengue Vaccine Research and Trials
  • Expansion of Vaccine Coverage in Endemic Regions Enhances Market Opportunities
  • Growing Public Health Initiatives Support Dengue Vaccination Programs
  • Integration of Dengue Vaccination in National Immunization Programs
  • Rising Travel and Migration Patterns Increase Demand for Dengue Vaccination
  • Growing Awareness Campaigns Enhance Public Acceptance of Dengue Vaccination
  • Growing Pediatric Population in Dengue-Prevalent Regions Drives Market Demand
  • Emergence of Vaccine Tourism in Dengue Endemic Regions

FOCUS ON SELECT PLAYERS (Total 44 Featured)

  • Biological E. Ltd.
  • GlaxoSmithKline plc
  • Instituto Butantan
  • Panacea Biotec Ltd.
  • Sanofi SA
  • Takeda Pharmaceuticals Company Ltd.
  • Vabiotech

For more information about this report visit https://www.researchandmarkets.com/r/pkli01

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

 
Dengue Vaccine Market

Contact Data